1. At a Glance
The pharmaceutical market is often viewed as a defensive stronghold, yet specialized oncology players face unique risks. Beta Drugs Ltd presents an intriguing case: top-line numbers are moving up, but a deeper look at the balance sheet reveals structural strains that require careful analysis.
With annual consolidated revenue touching ₹385 crore in FY26, up from ₹362 crore in FY25, the company has successfully expanded its footprint. However, this growth has come at a significant cost to liquidity. The business is currently dealing with a severe working capital lock-up, with Gross Current Asset (GCA) days standing at an intense 190 to 260 days. This indicates that capital is heavily tied up in the operational pipeline.
Revenue Growth (₹362 cr → ₹385 cr) → Inventory Surge (127 days → 159 days) → Operating Cash Flow Drop (₹36 cr → ₹31 cr)
At the same time, inventory holding periods have lengthened from 127 days to 159 days over the past year. Receivables are also stretched out to 113 days. This combination shows that while products are being shipped, cash collections are laggy, and unsold stock is accumulating on the balance sheet.
Compounding these operational friction points is a sharp rise in total borrowings. Debt escalated from ₹13 crore in FY24 to ₹136.38 crore in FY25, and has now reached ₹147.80 crore in FY26. While management notes that a significant portion of this debt is tied to Compulsorily Convertible Debentures (CCDs) slated for equity conversion in June, the current capital structure carries clear near-term obligations.
Financially, Net Profit After Tax (PAT) dipped from ₹42.02 crore in FY25 to ₹41.51 crore in FY26, highlighting a divergence between top-line expansion and bottom-line delivery. Operating profit margins (OPM) remain stable at 18.82% for the latest quarter, but raw material price volatility and a shifting product mix present continuous margin pressure.
The company’s strategic move into the cosmetology/dermatology space and the ₹69.40 crore acquisition of a 66.09% stake in Nivian Lifesciences introduce additional execution risks. This sets up an intriguing tension between aggressive corporate expansion and tightening balance sheet metrics.
2. Introduction
Beta Drugs Ltd operates as a specialized developer and manufacturer of oncology (anti-cancer) formulations and Active Pharmaceutical Ingredients (APIs). The corporate structure relies heavily on a fully consolidated model, integrating its core operations with two wholly-owned subsidiaries: Adley Formulations Pvt Ltd (focused on domestic tablet and injectable manufacturing) and Adley Lab Ltd (handling backward integrated cytotoxic API production).
The company’s operating profile is split across four primary segments:
- Contract Development and Manufacturing Operations (CDMO)
- Domestic Own Brands
- International Business
- Bulk API sales
Over the last few fiscal cycles, the leadership team has pursued an aggressive strategy aimed at transforming the business from a pure-play contract manufacturer into a brand-led, export-driven oncology house. This shift involves moving entire asset bases and separating domestic production lines from export-oriented plants.
The standalone facility at Beta Drugs is being converted into a dedicated export hub targeting regulated markets such as Europe, Latin America, and South Africa. Meanwhile, high-volume domestic CDMO work is being shifted to Adley Formulations.
Financially, this transition has created a temporary mismatch: compliance, bioequivalence studies, and facility upgrade costs are being recognized immediately, while the resulting regulated export revenue streams remain back-ended.
Additionally, the corporate narrative is shaped by recent capital market actions. This includes a transition to the National Stock Exchange (NSE) Main Board in late 2025 and a major preferential equity issuance to fund external acquisitions.
The central analytical question is whether the cash generated by the core oncology business can sustain this multipronged expansion into dermatology and IVF therapies, or if the intense working capital cycle will limit the company’s financial flexibility.
3. Business Model – What Do They Actually Do?
At its core, Beta Drugs operates an asset-heavy, highly regulated chemical-to-formulation production flow. The company maintains two formulation units and one dedicated chemical synthesis plant for cytotoxic APIs, producing roughly 70% of its key starting materials internally.
The contract manufacturing business (CDMO) accounts for approximately 39% of total revenue. In this segment, the company acts as an outsourced production partner for over 50 pharmaceutical brands, including major players like Glenmark, Torrent Pharma, Reliance Lifesciences, and Cadila. While this business provides steady, recurring volumes, it operates on a lower margin profile. Management estimates CDMO EBITDA margins at around 16% to 17%, and the business is highly sensitive to product mix shifts.
The Domestic Branded business contributes 36% of sales and functions through a direct hospital-procurement network. Oncology drugs are marketed under proprietary labels like Canrib, Adcilib, and Cazfila-OS across 100 stock-keeping units (SKUs).
Because oncology purchasing decisions are concentrated within institutional accounts, corporate networks, and state-funded cancer centers (such as HCG, Artemis, and HLL Lifecare), growth here depends on increasing the medical prescriber base and launching specialized New Drug Delivery Systems (NDDS).
The International Export segment accounts for 18% of sales and operates on a tender-driven model across 46 semi-regulated and developing nations. This business model is highly seasonal: global health tenders are typically awarded in the third and fourth quarters, leading to volatile shipping schedules.
The company’s newest segment is a cosmetology and dermatology line. This business uses an in-licensing model for European aesthetic fillers and mesotherapy products, moving the company away
